Shionogi's naldemedine meets Phase III endpoints for opioid-induced constipation

Japan's Shionogi said it met the primary and secondary endpoints for a Phase III clinical trial on naldemedine for the treatment of opioid-induced constipation in adult patients with chronic noncancer pain receiving opioid therapy. "OIC is one of the most common side effects of chronic opioid therapy, and can negatively impact a person's quality of life, including limitations in daily activities, impairments in psychological well-being, and decreases in work productivity," Dr. Juan Camilo Arjona Ferreira, senior vice president of clinical development, said in a release. Release